Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Clinical Trial Source, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,305,709

131 payments

Through program year 2023, Clinical Trial Source, LLC is reported as receiving $1,305,709 in research payments, across 131 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $214,266 5
2022 Research $268,415 51
2021 Research $226,195 60
2020 Research $434,892 9
2019 Research $161,942 6

Breakdown

Who paid Research payments · program years 2019–2023
  1. Organon LLC $434,878 38 payments
  2. Biogen, Inc. $389,725 6 payments
  3. BeiGene, Ltd. $178,748 40 payments
  4. Eisai Inc. $161,617 5 payments
  5. Corcept Therapeutics $55,412 21 payments
  6. H. Lundbeck A S $45,167 3 payments
  7. SCYNEXIS, Inc. $16,045 5 payments
  8. Jazz Pharmaceuticals Inc. $7,349 4 payments
  9. Genentech, Inc. $7,294 1 payment
  10. Applied Therapeutics, inc. $3,500 4 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $245,719 2 payments
  2. Og-8175A-023 $224,263 35 payments
  3. Og-8175A-023 $210,615 3 payments
  4. A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years $161,617 5 payments
  5. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients With Mild-to-Moderate COVID-19 $157,934 30 payments
  6. Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $97,326 1 payment
  7. Cort118335-877 $55,412 21 payments
  8. Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) $45,167 3 payments
  9. Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis $28,442 1 payment
  10. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19 $20,814 10 payments
What the money was spent on Research payments · program years 2019–2023
  1. Patient care $449,923 42 payments
  2. Overhead $1,000 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record